Conflicts of Interest Between Physicians and the Pharmaceutical Industry and Special Interest Groups

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 1, 2008, Pages 113-125

  Schetky, Diane H ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CONFLICT OF INTEREST; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; GOVERNMENT REGULATION; HUMAN; MEDICAL EDUCATION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIST; REVIEW;

ADOLESCENT PSYCHIATRY; ADVERTISING AS TOPIC; CHILD PSYCHIATRY; CONFLICT OF INTEREST; CONGRESSES AS TOPIC; DRUG INDUSTRY; EDUCATION, MEDICAL, CONTINUING; ETHICS, MEDICAL; FINANCIAL SUPPORT; GIFT GIVING; HUMANS; MARKETING; REFERRAL AND CONSULTATION; UNITED STATES;

EID: 36148997715     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2007.07.007     Document Type: Review

References (39)

1. Thompson D.F. Understanding financial conflicts of interest. N Engl J Med 329 8 (1993) 573-576
2. IMS Health Financial, business and trade releases. Available at: http://www.IMS_Japan.cojp/industry_trends_press_releases_2007. Accessed September 4, 2007.
3. Angell M. The truth about drug companies (2005), Random House, New York
4. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift?. JAMA 283 (2000) 373-380
5. Saul S. Doctors and drug makers: a move to end cozy ties. New York: New York Times 2007. p. C1.
6. Elliott C. The drug pushers. The Atlantic Monthly. April 2006; 82-93.
7. Public Citizen Congress Watch. 2002 Drug industry profits: hefty pharmaceutical company margins dwarf other industries. Available at: http://www.citizen.org/congress/reform/drug_industry/coproratearticles.cfm?ID=9923.
8. Peterson M. Suit says company promoted drug in exam rooms. New York Times 1 (May 15, 2001)
9. Orlowski J.P., and Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 02 1 (1992) 270-273
10. Berenson A. Drug files show maker promoted unapproved use. New York Times. December 18, 2006; A1.
11. Brodkey A. The role of the pharmaceutical industry in teaching psychopharmacology: a growing problem. Acad Psychiatry 29 (2005) 222-229
12. Wilkes M.S., Doblin B.H., and Shapiro M.F. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 116 11 (1992) 912-919
13. Galt K., Rich E., and Kralewski J. Group practice strategies to manage pharmaceutical cost in an HMO network. Am J Manag Care 7 (2001) 1081-1090
14. Bekelman E., Yan L., and Gross P. Scope and impact of financial conflicts of interest in biomedical research. JAMA 289 (2003) 454-465
15. Jacobs P. How profits, research mix at Stanford. Available at: http://www.matr.net/article_19768html1-18k.
16. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med 342 (2000) 1539-1544
17. Anders T. Enhancing transparency of research: antidepressant medications for children and adolescents. Statement from Thomas Anders, M.D. President of the American Academy of Child and Adolescent Psychiatry. Washington, DC, February 6, 2007. Available at: http://www.aacap.org, media, press releases. Accessed September 5, 2007.
18. Meier B. Contracts keep drug research out of reach. New York Times. November 29, 2004. 2004; 29
19. Angell M. Is academic medicine for sale?. N Engl J Med 342 (2000) 1516-1518
20. Standbridge J.B. Of doctor conventions and drug companies. Fam Med 38 (2006) 518-521
21. Lurie P., Tran T., Manuel S., et al. Violations of exhibiting and FDA rules at an American Psychiatric Association Annual Meeting. J Public Health Policy 26 (2005) 389-399
22. Kassirer JP. Doctors and drug companies. Boston Globe. July 6, 2005; 15.
23. Relman A. Defending professional independence. ACGME's proposed new guidelines for support of CME. JAMA 14 (2003) 03
24. APA Annual Report 2006 Arlington, VA: American Pspychiatric Association.
25. Hensley D., and Martinez B. Speaker programs come under the microscope again. To sell their drugs, companies increasingly rely on doctors. Wall Street Journal (2005) section A: 1
26. Kassirer J.P. When physician-industry interactions go awry. J Pediatr 149 (2006) S43-S46
27. Topol E., and Blumenthal D. Physicians and the investment industry. JAMA 293 (2005) 2654-2657
28. Harris G, Robert J. Doctor's ties to drug makers are put on close view. New York Times. March 21, 2007; A1.
29. Harris G. Ten voters on panel backing pain pills had industry ties. New York Times 24 (2005) A1
30. Harris G. FDA rule limits role of advisers tied to industry. New York Times. March 22, 2007; A1.
31. American Academy of Child and Adolescent Psychiatry. Guidelines for commercial contributions to the AACAP. Available at: http://www.aacap.org.
32. American Medical Association. Ethical opinions and guidelines. 2005. Updated clarification on Opinion E-8.061: Gifts to physicians from industry.
33. Cooney E. Project seeks to limit ties between doctors, drug companies. White Coat Notes: news from the Boston medical community [Boston Globe]. Available at: http://boston.com/yourlife/health/blog/2007/02/prescription-pr.html. Accessed September 5, 2007.
34. Brennan T.A., Rothman D.J., Blank L., et al. Health industry practices that create conflicts of interest: a proposal for academic medical centers. JAMA 295 4 (2006) 429-430
35. Accreditation Council for Continuing Medical Education. Standards for commercial support: standards to ensure independence of CME activities. Available at: http://www.accme.org/index.cfm. Accesssed September 5, 2007.
36. American Student Medical Association. Principles regarding pharmaceuticals and medical devices 2005. Available at: http://www.amsa.org/ppp/pharm.cfm. Accessed September 4, 2007.
37. Pharmaceutical Research and Manufacturers of America, "Code on Interactions with Health Professionals." Available at: http://www.phrma.org/code-on=-interractions-withhealthcare-professionals/. Accessed September 4, 2007.
38. Dresser R. Pharmaceutical company gifts: from voluntary standards to legal demands. Hastings Cent Rep (2006) 8-9
39. Geppert C. Medical education and the pharmaceutical industry: a review of ethical guidelines and their implications for psychiatric training. Acad Psychiatry 31 (2007) 32-39